Societe L'oreal Sa

Centre International De Recherches Dermatologiques Galderma

Galderma Research & Development Snc

Centre International De Recherches Dermatologiques

Serge Michel

Jean R Maignan

Michel Rivier

Sylvie Genard

Michel Demarchez

Irina Safonova

Annie Ladoux

Barbara Vega

Marie-Cecile Lenoir-Viale

Christine Cathelineau

Christian Frelin

(poly)thiaalkynoic compounds and pharmaceutical/cosmetic compositions comprised thereof

The invention concerns the use of at least one activator of receptors of the PPAR-&ggr; type for preparing a pharmaceutical composition for treating skin disorders related to an anomaly of the differentiation of epidermic cells.

Use of ppar-&ggr; activators in dermatology

The retinoids, in particular the anti-AP-1 retinoids, effectively inhibit the expression of VEGF, and thus are useful for the therapeutic treatment of disease states manifesting an overexpression of VEGF.

Retinoid inhibition of expression of VEGF

Pharmaceutical/dermatological compositions comprising (a) at least one first ligand displaying selective activity for the RXR receptors and (b) at least one second ligand displaying selective activity for the RAR-.alpha. receptor, are useful for modulating the proliferation and/or differentiation of HL-60 type cells, in particular for the systemic treatment of acute promyelocytic leukemia.

Synergistic therapeutic compositions comprising at least one ligand

Growing community of inventors

Roquefort les Pins, France

Serge Michel